
MINERVA SURGICAL INC (UTRS) Fundamental Analysis & Valuation
NASDAQ:UTRS • US60343F2056
Current stock price
1.48 USD
-0.07 (-4.52%)
At close:
1.53 USD
+0.05 (+3.38%)
After Hours:
This UTRS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. UTRS Profitability Analysis
1.1 Basic Checks
- UTRS had negative earnings in the past year.
- In the past year UTRS has reported a negative cash flow from operations.
1.2 Ratios
- UTRS has a worse Return On Assets (-45.95%) than 66.17% of its industry peers.
- UTRS has a worse Return On Equity (-164.78%) than 77.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.95% | ||
| ROE | -164.78% | ||
| ROIC | N/A |
ROA(3y)-29.33%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- UTRS has a Gross Margin of 54.19%. This is comparable to the rest of the industry: UTRS outperforms 50.75% of its industry peers.
- In the last couple of years the Gross Margin of UTRS has grown nicely.
- UTRS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.19% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.06%
GM growth 5YN/A
2. UTRS Health Analysis
2.1 Basic Checks
- UTRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, UTRS has more shares outstanding
- Compared to 1 year ago, UTRS has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -6.13, we must say that UTRS is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -6.13, UTRS is not doing good in the industry: 70.65% of the companies in the same industry are doing better.
- UTRS has a Debt/Equity ratio of 1.37. This is a high value indicating a heavy dependency on external financing.
- UTRS has a Debt to Equity ratio of 1.37. This is amonst the worse of the industry: UTRS underperforms 82.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.37 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.13 |
ROIC/WACCN/A
WACC8.14%
2.3 Liquidity
- A Current Ratio of 1.88 indicates that UTRS should not have too much problems paying its short term obligations.
- UTRS's Current ratio of 1.88 is on the low side compared to the rest of the industry. UTRS is outperformed by 75.62% of its industry peers.
- UTRS has a Quick Ratio of 1.02. This is a normal value and indicates that UTRS is financially healthy and should not expect problems in meeting its short term obligations.
- UTRS has a Quick ratio of 1.02. This is amonst the worse of the industry: UTRS underperforms 81.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.02 |
3. UTRS Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 58.66% over the past year.
- UTRS shows a small growth in Revenue. In the last year, the Revenue has grown by 3.07%.
- The Revenue has been growing by 24.58% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)58.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.88%
Revenue 1Y (TTM)3.07%
Revenue growth 3Y24.58%
Revenue growth 5YN/A
Sales Q2Q%-4.92%
3.2 Future
- UTRS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.40% yearly.
- The Revenue is expected to grow by 10.85% on average over the next years. This is quite good.
EPS Next Y82.41%
EPS Next 2Y36.93%
EPS Next 3Y23.4%
EPS Next 5YN/A
Revenue Next Year2.99%
Revenue Next 2Y8.86%
Revenue Next 3Y10.85%
Revenue Next 5YN/A
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. UTRS Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for UTRS. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for UTRS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as UTRS's earnings are expected to grow with 23.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.93%
EPS Next 3Y23.4%
5. UTRS Dividend Analysis
5.1 Amount
- No dividends for UTRS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
UTRS Fundamentals: All Metrics, Ratios and Statistics
1.48
-0.07 (-4.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13 2023-11-13/amc
Earnings (Next)03-19 2024-03-19/amc
Inst Owners0.31%
Inst Owner Change0%
Ins Owners1799.28%
Ins Owner Change0%
Market Cap13.14M
Revenue(TTM)51.69M
Net Income(TTM)-33.45M
Analysts82.86
Price Target3.06 (106.76%)
Short Float %0%
Short Ratio0
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.06%
Min EPS beat(2)20.59%
Max EPS beat(2)45.53%
EPS beat(4)3
Avg EPS beat(4)16.45%
Min EPS beat(4)-6.95%
Max EPS beat(4)45.53%
EPS beat(8)5
Avg EPS beat(8)7.58%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-8.42%
Min Revenue beat(2)-11.14%
Max Revenue beat(2)-5.7%
Revenue beat(4)1
Avg Revenue beat(4)-3.51%
Min Revenue beat(4)-11.14%
Max Revenue beat(4)4.81%
Revenue beat(8)1
Avg Revenue beat(8)-2.78%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1250%
EPS NY rev (1m)0%
EPS NY rev (3m)-1750%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.25 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.65 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-8.21
EYN/A
EPS(NY)-2.95
Fwd EYN/A
FCF(TTM)-4.37
FCFYN/A
OCF(TTM)-4.36
OCFYN/A
SpS5.82
BVpS2.29
TBVpS-0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.95% | ||
| ROE | -164.78% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.19% | ||
| FCFM | N/A |
ROA(3y)-29.33%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.06%
GM growth 5YN/A
F-Score2
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.37 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0.57% | ||
| Cap/Sales | 0.1% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | -6.13 |
F-Score2
WACC8.14%
ROIC/WACCN/A
Cap/Depr(3y)4.15%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.81%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.88%
EPS Next Y82.41%
EPS Next 2Y36.93%
EPS Next 3Y23.4%
EPS Next 5YN/A
Revenue 1Y (TTM)3.07%
Revenue growth 3Y24.58%
Revenue growth 5YN/A
Sales Q2Q%-4.92%
Revenue Next Year2.99%
Revenue Next 2Y8.86%
Revenue Next 3Y10.85%
Revenue Next 5YN/A
EBIT growth 1Y9.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.05%
EBIT Next 3Y11.17%
EBIT Next 5YN/A
FCF growth 1Y-185.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-198.46%
OCF growth 3YN/A
OCF growth 5YN/A
MINERVA SURGICAL INC / UTRS Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for MINERVA SURGICAL INC?
ChartMill assigns a fundamental rating of 2 / 10 to UTRS.
What is the valuation status for UTRS stock?
ChartMill assigns a valuation rating of 1 / 10 to MINERVA SURGICAL INC (UTRS). This can be considered as Overvalued.
What is the profitability of UTRS stock?
MINERVA SURGICAL INC (UTRS) has a profitability rating of 1 / 10.
Can you provide the financial health for UTRS stock?
The financial health rating of MINERVA SURGICAL INC (UTRS) is 1 / 10.